At ISSCR Lonza recently introduced its new L7™ hiPSC Reprogramming and hPSC Culture System for basic stem-cell research, disease modeling, drug development and regenerative medicine. The L7™ System will support the generation of reproducible, clinically relevant data as a solid basis for more efficient drug development and accelerated progress in regenerative medicine.

The innovative L7™ hiPSC Reprogramming and hPSC Culture System listed below include seven key components that are designed to work together as a robust workflow:

1.  Clonetics™ and Poietics™ Primary Cells
2.  Nucleofector™ Technology
3.  L7TM Reprogramming Bundles for PBMCs and fibroblasts – coming soon
4.  L7TM hPSC Medium
5.  L7TM hPSC Matrix
6.  L7TM hPC Passaging Solution
7.  L7TM hPSC Cryosolution

This novel system is the only complete solution on the market for the generation of induced pluripotent stem-cells (iPSCs) as well as the maintenance of human embryonic stem-cells (hESCs) and iPSCs under defined, xeno-free conditions. The...

About Lonza 
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.


Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?